药物治疗注意力缺陷/多动障碍对日后精神病合并症的影响:一项基于人群的前瞻性长期研究。

0 PSYCHIATRY
Ingvild Lyhmann,Tarjei Widding-Havneraas,Ingvar Bjelland,Simen Markussen,Felix Elwert,Ashmita Chaulagain,Arnstein Mykletun,Anne Halmøy
{"title":"药物治疗注意力缺陷/多动障碍对日后精神病合并症的影响:一项基于人群的前瞻性长期研究。","authors":"Ingvild Lyhmann,Tarjei Widding-Havneraas,Ingvar Bjelland,Simen Markussen,Felix Elwert,Ashmita Chaulagain,Arnstein Mykletun,Anne Halmøy","doi":"10.1136/bmjment-2024-301003","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nPsychiatric comorbidity is frequent among persons with attention-deficit/hyperactivity disorder (ADHD). Whether pharmacological treatment of ADHD influences the incidence of psychiatric comorbidity is uncertain.\r\n\r\nOBJECTIVE\r\nTo investigate associations and causal relations between pharmacological treatment of ADHD and incidence of subsequent comorbid psychiatric diagnoses.\r\n\r\nMETHODS\r\nWe employed registry data covering all individuals aged 5-18 years in Norway who were diagnosed with ADHD during 2009-2011 (n=8051), followed until 2020. We used linear probability models (LPM) and instrumental variable (IV) analyses to examine associations and causal effects, respectively, between pharmacological treatment and subsequent comorbidity.\r\n\r\nFINDINGS\r\nFrom time of ADHD diagnosis to 9 years of follow-up, 63% of patients were registered with comorbid psychiatric disorders. For males, LPM showed associations between ADHD medication and several incident comorbidities, but strength and direction of associations and consistency over time varied. For females, no associations were statistically significant. IV analyses for selected categories isolating effects among patients 'on the margin of treatment' showed a protective effect for a category of stress-related disorders in females and for tic disorders in males for the first 2 and 3 years of pharmacological treatment, respectively.\r\n\r\nCONCLUSIONS\r\nOverall, LPM and IV analyses did not provide consistent or credible support for long-term effects of pharmacological treatment on later psychiatric comorbidity. However, IV results suggest that for patients on the margin of treatment, pharmacological treatment may initially reduce the incidence of certain categories of comorbid disorders.\r\n\r\nCLINICAL IMPLICATIONS\r\nClinicians working with persons with ADHD should monitor the effects of ADHD medication on later psychiatric comorbidity.\r\n\r\nTRIAL REGISTRATION NUMBER\r\nISRCTN11891971.","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of pharmacological treatment of attention-deficit/hyperactivity disorder on later psychiatric comorbidity: a population-based prospective long-term study.\",\"authors\":\"Ingvild Lyhmann,Tarjei Widding-Havneraas,Ingvar Bjelland,Simen Markussen,Felix Elwert,Ashmita Chaulagain,Arnstein Mykletun,Anne Halmøy\",\"doi\":\"10.1136/bmjment-2024-301003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\r\\nPsychiatric comorbidity is frequent among persons with attention-deficit/hyperactivity disorder (ADHD). Whether pharmacological treatment of ADHD influences the incidence of psychiatric comorbidity is uncertain.\\r\\n\\r\\nOBJECTIVE\\r\\nTo investigate associations and causal relations between pharmacological treatment of ADHD and incidence of subsequent comorbid psychiatric diagnoses.\\r\\n\\r\\nMETHODS\\r\\nWe employed registry data covering all individuals aged 5-18 years in Norway who were diagnosed with ADHD during 2009-2011 (n=8051), followed until 2020. We used linear probability models (LPM) and instrumental variable (IV) analyses to examine associations and causal effects, respectively, between pharmacological treatment and subsequent comorbidity.\\r\\n\\r\\nFINDINGS\\r\\nFrom time of ADHD diagnosis to 9 years of follow-up, 63% of patients were registered with comorbid psychiatric disorders. For males, LPM showed associations between ADHD medication and several incident comorbidities, but strength and direction of associations and consistency over time varied. For females, no associations were statistically significant. IV analyses for selected categories isolating effects among patients 'on the margin of treatment' showed a protective effect for a category of stress-related disorders in females and for tic disorders in males for the first 2 and 3 years of pharmacological treatment, respectively.\\r\\n\\r\\nCONCLUSIONS\\r\\nOverall, LPM and IV analyses did not provide consistent or credible support for long-term effects of pharmacological treatment on later psychiatric comorbidity. However, IV results suggest that for patients on the margin of treatment, pharmacological treatment may initially reduce the incidence of certain categories of comorbid disorders.\\r\\n\\r\\nCLINICAL IMPLICATIONS\\r\\nClinicians working with persons with ADHD should monitor the effects of ADHD medication on later psychiatric comorbidity.\\r\\n\\r\\nTRIAL REGISTRATION NUMBER\\r\\nISRCTN11891971.\",\"PeriodicalId\":72434,\"journal\":{\"name\":\"BMJ mental health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ mental health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjment-2024-301003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"0\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ mental health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjment-2024-301003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

背景注意缺陷/多动障碍(ADHD)患者经常合并精神疾病。我们采用的登记数据涵盖了挪威所有在2009-2011年期间被诊断为多动症的5-18岁患者(人数=8051),并跟踪调查至2020年。我们使用线性概率模型(LPM)和工具变量分析(IV)分别研究了药物治疗与后续合并症之间的关联和因果效应。结果从诊断出多动症到随访9年期间,63%的患者登记患有合并精神障碍。在男性患者中,LPM显示ADHD药物治疗与几种并发症之间存在关联,但关联的强度和方向以及随时间变化的一致性各不相同。就女性而言,两者之间没有统计学意义上的关联。对 "处于治疗边缘 "的患者进行的特定类别的IV分析表明,在药物治疗的前2年和前3年,对女性的一类应激相关障碍和男性的抽搐障碍分别有保护作用。临床启示从事多动症治疗的临床医生应监测多动症药物治疗对日后精神疾病合并症的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of pharmacological treatment of attention-deficit/hyperactivity disorder on later psychiatric comorbidity: a population-based prospective long-term study.
BACKGROUND Psychiatric comorbidity is frequent among persons with attention-deficit/hyperactivity disorder (ADHD). Whether pharmacological treatment of ADHD influences the incidence of psychiatric comorbidity is uncertain. OBJECTIVE To investigate associations and causal relations between pharmacological treatment of ADHD and incidence of subsequent comorbid psychiatric diagnoses. METHODS We employed registry data covering all individuals aged 5-18 years in Norway who were diagnosed with ADHD during 2009-2011 (n=8051), followed until 2020. We used linear probability models (LPM) and instrumental variable (IV) analyses to examine associations and causal effects, respectively, between pharmacological treatment and subsequent comorbidity. FINDINGS From time of ADHD diagnosis to 9 years of follow-up, 63% of patients were registered with comorbid psychiatric disorders. For males, LPM showed associations between ADHD medication and several incident comorbidities, but strength and direction of associations and consistency over time varied. For females, no associations were statistically significant. IV analyses for selected categories isolating effects among patients 'on the margin of treatment' showed a protective effect for a category of stress-related disorders in females and for tic disorders in males for the first 2 and 3 years of pharmacological treatment, respectively. CONCLUSIONS Overall, LPM and IV analyses did not provide consistent or credible support for long-term effects of pharmacological treatment on later psychiatric comorbidity. However, IV results suggest that for patients on the margin of treatment, pharmacological treatment may initially reduce the incidence of certain categories of comorbid disorders. CLINICAL IMPLICATIONS Clinicians working with persons with ADHD should monitor the effects of ADHD medication on later psychiatric comorbidity. TRIAL REGISTRATION NUMBER ISRCTN11891971.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信